Parallel Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Parallel Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.36K	Buy	+103	New	+$1.37K	﹤0.01%	3719
2026 Q1	–	Sell	-51	Closed	-$804	–	3871
2025 Q4	$804	Buy	+51	New	+$648	﹤0.01%	3331
2023 Q3	–	Sell	-13	Closed	-$278	–	3401
2023 Q2	$278	Buy	+13	New	+$383	﹤0.01%	3203
2022 Q2	–	Sell	-164	Closed	-$11K	–	3075
2022 Q1	$11K	Sell	164 -587	-78%	-$38.2K	﹤0.01%	1955
2021 Q4	$56K	Sell	751 -14	-2%	-$1.1K	﹤0.01%	1259
2021 Q3	$43K	Buy	765 +667	+681%	+$33K	﹤0.01%	1338
2021 Q2	$4K	Buy	98 +51	+109%	+$2.5K	﹤0.01%	2356
2021 Q1	$2K	Hold	47	–	–	﹤0.01%	2457
2020 Q4	$2K	Sell	47 -53	-53%	-$2.33K	﹤0.01%	2294
2020 Q3	$5K	Buy	100 +65	+186%	+$3.15K	﹤0.01%	2006
2020 Q2	$1K	Buy	+35	New	+$1.81K	﹤0.01%	2308
2018 Q2	–	Sell	-348	Closed	-$28K	–	2117
2018 Q1	$28K	Buy	+348	New	+$26.8K	﹤0.01%	874

Other funds holding ENTA

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Northeast Investment Management Boston, Massachusetts $2.79B AUM 21.78% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Parallel Advisors's ENTA Position: Q3 2026 in Review

Parallel Advisors opened a new position in Enanta Pharmaceuticals (ENTA) in Q3 2026: 103 shares worth $1.36K. The stake represents ﹤0.01% of the portfolio and ranks #3719 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in ENTA as recently as Q4 2025.

Parallel Advisors first reported a position in ENTA in Q1 2018 and has held it in 12 quarters since. The position peaked at $56K in Q4 2021. 29 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

Parallel Advisors held 103 shares of Enanta Pharmaceuticals worth $1.36K as of Q3 2026.
Enanta Pharmaceuticals was a new Parallel Advisors position in Q3 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3719 holding.
Parallel Advisors first reported a position in Enanta Pharmaceuticals in Q1 2018 and has held it in 12 quarters since.
Parallel Advisors's Enanta Pharmaceuticals position peaked at $56K in Q4 2021.
29 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.